Vor Biopharma, Inc. (VOR)
22.71
-0.65
(-2.78%)
USD |
NASDAQ |
Aug 24, 16:00
22.71
0.00 (0.00%)
After-Hours: 20:00
Vor Biopharma Debt to Equity Ratio : -0.0144 for June 30, 2026
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.0144 |
| March 31, 2026 | -0.0195 |
| December 31, 2025 | -0.0183 |
| September 30, 2025 | -0.0014 |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 0.4659 |
| December 31, 2024 | 0.3293 |
| September 30, 2024 | 0.4503 |
| June 30, 2024 | 0.3448 |
| March 31, 2024 | 0.2824 |
| December 31, 2023 | 0.2366 |
| September 30, 2023 | 0.2094 |
| June 30, 2023 | 0.1835 |
| March 31, 2023 | 0.167 |
| Date | Value |
|---|---|
| December 31, 2022 | 0.1553 |
| September 30, 2022 | 0.2538 |
| June 30, 2022 | 0.2389 |
| March 31, 2022 | 0.1489 |
| December 31, 2021 | 0.0833 |
| September 30, 2021 | 0.0756 |
| June 30, 2021 | 0.0715 |
| March 31, 2021 | 0.0684 |
| December 31, 2020 | 0.379 |
| September 30, 2020 | 0.2919 |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Dyne Therapeutics, Inc. | 0.3323 |
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 481.05M |
| Total Liabilities (Quarterly) | 681.25M |
| Shareholders Equity (Quarterly) | -200.20M |
| Current Ratio | 19.15 |
| Net Debt Paydown Yield | 0.56% |